公开(公告)号：US08906309B2

公开(公告)日：2014-12-09

申请号：US12767611

申请日：2010-04-26

申请人： Martin Krockenberger ,  Jiong Wu ,  Bodo Roemer ,  Giacomo Vacca

发明人： Martin Krockenberger ,  Jiong Wu ,  Bodo Roemer ,  Giacomo Vacca

IPC分类号： G01N33/00 ,  G01N31/00 ,  G01N15/00 ,  G01N15/14 ,  G01N33/49

CPC分类号： G01N15/1404 ,  G01N15/00 ,  G01N15/1429 ,  G01N15/1459 ,  G01N21/53 ,  G01N33/49 ,  G01N33/4915 ,  G01N33/492 ,  G01N2015/0073 ,  G01N2015/0076 ,  G01N2015/008 ,  G01N2015/0084 ,  G01N2015/1006 ,  G01N2015/1486 ,  G01N2800/22 ,  Y10T436/101666

摘要： A method for identifying, analyzing, and quantifying the cellular components of whole blood by use of an automated hematology analyzer and the detection of the light scattered, absorbed, and fluorescently emitted by each cell. More particularly, the aforementioned method involves identifying, analyzing, and quantifying the cellular components of whole blood by use of a light source having a wavelength ranging from about 400 nm to about 450 nm and multiple in-flow optical measurements and staining without the need for lysing red blood cells.

摘要翻译： 一种通过使用自动血液分析仪来鉴定，分析和定量全血细胞成分的方法，以及每个细胞散射，吸收和荧光发射的光的检测。 更具体地，上述方法包括通过使用波长范围为约400nm至约450nm的光源和多次流入光学测量和染色来识别，分析和定量全血的细胞组分，并且不需要 裂解红细胞。

公开(公告)号：US20140057270A1

公开(公告)日：2014-02-27

申请号：US13957945

申请日：2013-08-02

申请人： Quest Diagnostics Investments Incorporated

发明人： Maher Albitar ,  Wanlong Ma

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12N9/1205 ,  C12Q1/6869 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Y207/10002 ,  G01N33/573 ,  G01N2333/91205 ,  G01N2800/22 ,  G01N2800/56

摘要： The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides compositions and methods useful for diagnosing hematopoietic diseases including, for example, myeloproliferalive diseases. The invention also provides compositions and methods useful for determining a prognosis of an individual diagnosed as having a hematopoietic disease.

摘要翻译： 本文公开的本发明基于鉴定JAK2基因和JAK2蛋白中的新突变。 本发明提供了用于诊断造血疾病的组合物和方法，包括例如骨髓增生性疾病。 本发明还提供了用于确定被诊断患有造血疾病的个体的预后的组合物和方法。

公开(公告)号：US08623659B2

公开(公告)日：2014-01-07

申请号：US13238272

申请日：2011-09-21

申请人： Tim R. Randolph

发明人： Tim R. Randolph

IPC分类号： G01N33/72 ,  G01N33/48 ,  G01N21/63 ,  C12Q1/02

CPC分类号： G01N33/6893 ,  G01N33/5091 ,  G01N33/52 ,  G01N33/721 ,  G01N33/726 ,  G01N2800/22

摘要： The present invention provides a method for determining sickle-cell zygosity in a subject. The method involves forming a first solution which includes a sample from the subject, a phosphate buffer, a detergent, and a reducing agent and subjecting the first solution to centrifugation to form a second solution and a supernatant; and taking a color reading of the supernatant and of the second solution; optionally filtering the second solution to form a filtrate and a precipitate, and optionally measuring the amount of the precipitation and the absorbance of the filtrate or taking a color reading of the filtrate.

摘要翻译： 本发明提供了一种用于确定受试者中镰状细胞接合性的方法。 该方法包括形成包含来自受试者的样品，磷酸盐缓冲液，洗涤剂和还原剂的第一溶液，并使第一溶液离心以形成第二溶液和上清液; 并取上清液和第二溶液的颜色读数; 任选地过滤第二溶液以形成滤液和沉淀物，并且任选地测量滤液的沉淀量和吸光度或进行滤液的彩色读数。

公开(公告)号：US20130196346A1

公开(公告)日：2013-08-01

申请号：US13739250

申请日：2013-01-11

申请人： The Trustees of the University of Pennsylvania

发明人： Jonni MOORE ,  Sindhu Cherian ,  Adam Bagg

IPC分类号： G01N33/50

CPC分类号： G01N33/5091 ,  B82Y5/00 ,  B82Y10/00 ,  G01N33/5094 ,  G01N2333/70553 ,  G01N2333/70589 ,  G01N2800/22 ,  Y10S435/973 ,  Y10S436/811 ,  Y10S436/813 ,  Y10T436/101666 ,  Y10T436/13

摘要： The present invention relates to methods and kits for diagnosing, ascertaining the clinical course of myelodysplastic syndrome (MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.

摘要翻译： 本发明涉及用于诊断，确定骨髓增生异常综合征（MDS）的临床过程并确定对骨髓增生异常综合征治疗方案的反应的方法和试剂盒。 具体地，本发明提供了可用于诊断和确定与MDS相关的临床参数的方法和试剂盒，其基于MDS特有的表面标记。

公开(公告)号：US20130034862A1

公开(公告)日：2013-02-07

申请号：US13596579

申请日：2012-08-28

申请人： Wendy J. Fantl ,  David B. Rosen ,  Alessandra Cesano ,  Santosh K. Putta ,  James R. Hackett ,  Michael Walker ,  Jing Shi

发明人： Wendy J. Fantl ,  David B. Rosen ,  Alessandra Cesano ,  Santosh K. Putta ,  James R. Hackett ,  Michael Walker ,  Jing Shi

IPC分类号： G01N21/64 ,  G01N21/76

CPC分类号： G01N33/57426 ,  A61K31/4709 ,  A61K31/513 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/7076 ,  G01N33/50 ,  G01N33/5041 ,  G01N33/5044 ,  G01N33/5047 ,  G01N33/5055 ,  G01N33/5073 ,  G01N33/5094 ,  G01N33/53 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/6893 ,  G01N2333/705 ,  G01N2800/22 ,  G01N2800/52

摘要： The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN.

摘要翻译： 本发明提供了用于确定单细胞中多种蛋白质的活化状态的方法。 这种方法允许基于活化状态，表达标志物和其他标准快速检测复杂细胞群体中的异质性，以及在细胞群体内表现出相关的激活变化的细胞亚群的鉴定。 此外，这种方法允许细胞活动或性质的相关性。 此外，使用细胞激活的调节剂允许表征途径和细胞群体。 可以使用本发明分析的几种示例性疾病包括AML，MDS和MPN。

公开(公告)号：US20120028276A1

公开(公告)日：2012-02-02

申请号：US13019167

申请日：2011-02-01

申请人： Jonni MOORE ,  Sindhu Cherian ,  Adam Bagg

发明人： Jonni MOORE ,  Sindhu Cherian ,  Adam Bagg

IPC分类号： G01N21/64 ,  C12Q1/02

CPC分类号： G01N33/5091 ,  B82Y5/00 ,  B82Y10/00 ,  G01N33/5094 ,  G01N2333/70553 ,  G01N2333/70589 ,  G01N2800/22 ,  Y10S435/973 ,  Y10S436/811 ,  Y10S436/813 ,  Y10T436/101666 ,  Y10T436/13

摘要： The present invention relates to methods and kits for diagnosing, ascertaining the clinical course of myelodysplastic syndrome (MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.

摘要翻译： 本发明涉及用于诊断，确定骨髓增生异常综合征（MDS）的临床过程并确定对骨髓增生异常综合征治疗方案的反应的方法和试剂盒。 具体地，本发明提供了可用于诊断和确定与MDS相关的临床参数的方法和试剂盒，其基于MDS特有的表面标记。

公开(公告)号：US20120009608A1

公开(公告)日：2012-01-12

申请号：US12832608

申请日：2010-07-08

申请人： Barbara BOTTAZZI ,  Alberto Mantovani ,  Tiziano Barbui ,  Alessandro Rambaldi

发明人： Barbara BOTTAZZI ,  Alberto Mantovani ,  Tiziano Barbui ,  Alessandro Rambaldi

IPC分类号： G01N33/543 ,  G01N33/566

CPC分类号： G01N33/6893 ,  G01N2800/22 ,  G01N2800/222 ,  G01N2800/52

摘要： The invention provides a method for monitoring the progression of a myeloproliferative disease, particularly Polycythemia Vera (PV) and Essential Thrombocythemia (ET), or the response to pharmacological treatment with JAK2 inhibitors in a patient diagnosed positive for the same disease, or a method for predicting thrombotic events in a patient affected by the same myeloproliferative diseases, based on the measurement of PTX3 concentration in a blood, plasma or serum sample.

摘要翻译： 本发明提供了一种用于监测骨髓增生性疾病，特别是红细胞增多症（PV）和基础性血小板增多症（ET）进展的方法，或对于同一疾病诊断为阳性的患者中用JAK2抑制剂进行药理学治疗的反应或方法 基于血液，血浆或血清样品中PTX3浓度的测量，预测受相同骨髓增生性疾病影响的患者的血栓形成事件。

公开(公告)号：US20110319499A1

公开(公告)日：2011-12-29

申请号：US13002106

申请日：2009-06-30

申请人： Richard David Semba ,  Luigi Ferruci ,  Edward G. Lakatta

发明人： Richard David Semba ,  Luigi Ferruci ,  Edward G. Lakatta

IPC分类号： A61K47/40 ,  G01N33/566 ,  A61K47/16 ,  A61K47/42 ,  A61P3/10 ,  A61K47/14 ,  A61K47/02 ,  A61K47/04 ,  A61P13/12 ,  A61P9/10 ,  G01N33/53 ,  A61K47/38

CPC分类号： G01N33/5308 ,  A61K31/00 ,  A61K31/155 ,  A61K31/40 ,  A61K31/426 ,  A61K31/496 ,  A61K31/498 ,  A61K31/60 ,  A61K38/05 ,  G01N33/6893 ,  G01N2800/00 ,  G01N2800/10 ,  G01N2800/22 ,  G01N2800/32 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/52

摘要： The present invention provides compositions and methods for detecting carboxymethyl-lysine (CML) and circulating receptor for advanced glycation end (RAGE) products, and methods for correlating CML and RAGE levels with age-related disease, hi particular, serum CML and/or circulating receptor for advanced glycation end (RAGE) products can be used as a clinical biomarker in diagnostics to identify people who are at a higher risk of developing adverse ageing-related outcomes.

摘要翻译： 本发明提供用于检测羧甲基赖氨酸（CML）和晚期糖基化末端（RAGE）产物的循环受体的组合物和方法，以及将CML和RAGE水平与年龄相关疾病相关的方法，特别是血清CML和/或循环 用于晚期糖基化末端（RAGE）产物的受体可用作诊断中的临床生物标志物，以识别处于不利老龄化相关结果的更高风险的人群。

公开(公告)号：US08008028B2

公开(公告)日：2011-08-30

申请号：US12225477

申请日：2007-03-13

申请人： Kazuta Yasui ,  Fumiya Hirayama ,  Rika Furuta ,  Nobuki Matsuyama ,  Yoshitaka Kojima ,  Toru Miyazaki ,  Hisami Ikeda ,  Yoshihisa Watanabe

发明人： Kazuta Yasui ,  Fumiya Hirayama ,  Rika Furuta ,  Nobuki Matsuyama ,  Yoshitaka Kojima ,  Toru Miyazaki ,  Hisami Ikeda ,  Yoshihisa Watanabe

IPC分类号： G01N33/53 ,  C12N15/63

CPC分类号： G01N33/6854 ,  C12N2510/00 ,  G01N33/564 ,  G01N2333/70539 ,  G01N2800/22

摘要： A panel cell for detecting anti-HNA antibody is disclosed. The panel cell is obtained by introducing a DNA coding for an HNA antigen corresponding to the anti-HNA antibody into a cell so as to enable the expression of the DNA under the condition for use in the detection procedure, wherein the cell for DNA introduction exhibits no detectable reaction with anti-HLA-ABC antibody, anti-HLA-DR antibody, anti-HLA-DQ antibody, anti-HLA-DP antibody, anti-HNA-1 antibody, anti-HNA-2a antibody, anti-HNA-3a antibody, anti-HNA-4 antibody, anti-HNA-5 antibody, and serum from normal subject, in the detection procedure. The panel cell allows accurate and rapid detection of granulocyte antibody.

摘要翻译： 公开了一种用于检测抗-HNA抗体的细胞。 通过将编码对应于抗HNA抗体的HNA抗原的DNA导入细胞，使其能够在用于检测步骤的条件下使DNA表达，其中DNA引入的细胞显示出来 抗HLA-ABC抗体，抗HLA-DR抗体，抗HLA-DQ抗体，抗HLA-DP抗体，抗HNA-1抗体，抗HNA-2a抗体，抗HNA- 3a抗体，抗HNA-4抗体，抗-HNA-5抗体，以及来自正常受试者的血清。 面板细胞允许准确和快速检测粒细胞抗体。

公开(公告)号：US20100143379A1

公开(公告)日：2010-06-10

申请号：US11919307

申请日：2006-04-26

申请人： Richard Bucala ,  Lin Leng ,  Sarah Doernberg

发明人： Richard Bucala ,  Lin Leng ,  Sarah Doernberg

IPC分类号： A61K38/22 ,  C12Q1/68 ,  C07H21/04 ,  C40B40/06 ,  A61K31/7088 ,  A61K39/395 ,  G01N33/53 ,  A61P7/06 ,  A61P31/00

CPC分类号： C07K16/24 ,  A61K31/7088 ,  A61K38/1793 ,  A61K38/1816 ,  C07K16/2833 ,  C07K2317/76 ,  C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/172 ,  G01N33/6863 ,  G01N2333/70585 ,  G01N2800/12 ,  G01N2800/22 ,  G01N2800/26 ,  A61K2300/00

摘要： The present invention relates to methods and compositions for selecting a subject for treatment with an agonist or antagonist of macrophage migration inhibitory factor (MIF), identifying a subject at risk for developing a disease associated with high or low MIF expression, predicting the severity of a disease associated with high or low MIF expression in a subject, and for predicting whether a subject is susceptible to a disease associated with high or low MIF expression. The invention also provides novel methods of diagnosing a patient for a disease associated with high or low MIF expression. Also provided are methods for treating a subject having a disease or disorder associated with high or low MIF expression.

摘要翻译： 本发明涉及选择受试者用巨噬细胞迁移抑制因子（MIF）的激动剂或拮抗剂进行治疗的方法和组合物，鉴定出发生与高或低MIF表达相关的疾病的风险的受试者，预测a 与受试者的高或低MIF表达相关的疾病，以及用于预测受试者是否易感染与高或低MIF表达相关的疾病。 本发明还提供了诊断患者与高或低MIF表达相关疾病的新颖方法。 还提供了用于治疗患有与高或低MIF表达相关的疾病或病症的受试者的方法。